Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 5,147 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neoplasms, Germ Cell and Embryonal Clear all

Conditions: Glioblastoma Multiforme
Interventions: AQ4N, Temozolomide, Radiotherapy; Drug · Procedure
Lead sponsor: Novacea; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 5
States / cities: Los Angeles, California • Chicago, Illinois • Detroit, Michigan + 2 more

Conditions: Melanoma
Interventions: 6MHP, Montanide ISA-51, polyICLC, CDX-1127; Biological · Drug
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: Charlottesville, Virginia • Richmond, Virginia

Conditions: Neuroblastoma
Interventions: Not listed
Lead sponsor: New Approaches to Neuroblastoma Therapy Consortium; Other
Eligibility: 31 Days to 99 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2099
U.S. locations: 16
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 13 more

Conditions: Melanoma, Skin Neoplasms
Interventions: Axitinib [AG-013736]; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 11
States / cities: Orange, California • Miami Beach, Florida • Boston, Massachusetts + 5 more

Conditions: Recurrent Melanoma, Stage IV Melanoma, Tumors Metastatic to Brain
Interventions: Ipilimumab, Whole-Brain Radiation Therapy (WBRT), Stereotactic Radiosurgery (SRS); Drug · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 2
States / cities: Columbus, Ohio • Philadelphia, Pennsylvania

Conditions: Metastatic Medulloblastoma, High Risk Supratentorial PNET, Metastatic PNET
Interventions: Carboplatin, Vincristine, 24 Gy; Drug · Radiation
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 3 Years to 25 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Germ Cell Tumors, Hepatic Cancer, Neuroblastoma, Osteosarcoma, Rhabdomyosarcoma
Interventions: Recombinant Human Thrombopoietin; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Vestibular Disorder, Vestibular Schwannoma, Space Motion Sickness, Motion Sickness
Interventions: Traditional Therapy, SWAN; Behavioral · Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Baltimore, Maryland • Dayton, Ohio

Conditions: Breast Neoplasm, Hereditary Neoplastic Syndrome, Melanoma, Ovarian Neoplasm
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: Not listed
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2008
U.S. locations: 5
States / cities: Tucson, Arizona • Baltimore, Maryland • Ann Arbor, Michigan + 2 more

Conditions: Neuroblastoma
Interventions: Skin Biopsy, Gene Modified Neuroblastoma Cells; Procedure · Genetic
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 21 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Brain and Central Nervous System Tumors
Interventions: gefitinib, temozolomide; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • Bethesda, Maryland + 8 more

Conditions: Neuroendocrine Tumors
Interventions: Telotristat (Low-Dose), Telotristat (High-Dose); Drug
Lead sponsor: Lowell Anthony, MD; Other
Eligibility: 18 Years to 100 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Glioma, Glioblastoma
Interventions: Focused ultrasound (FUS); Device
Lead sponsor: InSightec; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 4
States / cities: Baltimore, Maryland • Boston, Massachusetts • Charlottesville, Virginia + 1 more

Conditions: Melanoma, Metastatic Melanoma, Solid Tumor, Neoplasm
Interventions: MLN2480; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 9
States / cities: San Francisco, California • Denver, Colorado • Augusta, Georgia + 6 more

Conditions: Brain and Central Nervous System Tumors
Interventions: imatinib mesylate; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • Bethesda, Maryland + 8 more

Conditions: Meningioma, Glioblastoma, Acoustic Neuroma, Brain Cancer, Pituitary Adenoma
Interventions: Panitumumab-IRDye800; Drug
Lead sponsor: Eben Rosenthal; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Neuroblastoma
Interventions: Topotecan, Cyclophosphamide, Cisplatin, Doxorubicin, Etoposide, Ifosfamide, Carboplatin, Peripheral Blood Stem Cell Transplant; Drug · Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 18 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2001
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Ocular Melanoma
Interventions: STA-9090; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Astrocytoma, Oligodendroglioma, Adult, Glioma, Malignant
Interventions: temporally-modulated pulsed radiotherapy (TMPRT); Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Liver Malignant Tumors, Cholangiocarcinoma Metastatic, Pancreatic Cancer, Melanoma
Interventions: high dose rate brachytherapy; Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 19 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Brain and Central Nervous System Tumors
Interventions: pyrazoloacridine, adjuvant therapy, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 8
States / cities: Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 5 more

Conditions: Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Neuroblastoma (NBL), Osteosarcoma
Interventions: Afamitresgene autoleucel; Genetic
Lead sponsor: USWM CT, LLC; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2038
U.S. locations: 10
States / cities: Palo Alto, California • Bethesda, Maryland • Boston, Massachusetts + 7 more

Conditions: Brain and Central Nervous System Tumors
Interventions: thalidomide, topotecan hydrochloride; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diffuse Intrinsic Pontine Glioma, Diffuse Pontine and Thalamic Gliomas, Diffuse Midline Glioma
Interventions: Infusate with MTX110 and gadolinium, Convection-Enhanced Delivery (CED); Drug · Device
Lead sponsor: Luca Szalontay; Other
Eligibility: 3 Years to 18 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme

Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

Neuroblastoma Biology Study

Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma

Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma

Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET)

Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy

StableEyes With Active Neurofeedback

Microarray Analysis for Human Genetic Disease

Using Gene Modified Neuroblastoma Cells for the Treatment of Relapsed/Refractory Neuroblastoma

Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma

Telotristat With Lutathera in Neuroendocrine Tumors

Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma

Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

Therapy for Children With Advanced Stage High Risk Neuroblastoma

STA-9090(Ganetespib) in Metastatic Ocular Melanoma

Temporally-modulated Pulsed Radiation Therapy (TMPRT) After Prior EBRT for Recurrent IDH-mutant Gliomas

High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies

Pyrazoloacridine Followed by Radiation Therapy in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme

SPEARHEAD-3 Pediatric Study

Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma

CED of MTX110 Newly Diagnosed Diffuse Midline Gliomas